Octave Bioscience
PrivateLast Round
Series C
Sep 4, 2025
Total Funding Raised
$139.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Octave Bioscience is a healthcare technology company that develops a clinical platform to generate, analyze, and integrate data for advancing care in multiple sclerosis and other neurodegenerative diseases while optimizing medication use and reducing overall healthcare costs.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Healthcare Analytics, Biotechnology
Business Model
B2B2C
Customer Profile
Services & Consulting, Usage-Based SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Octave Bioscience Comparables
Compare Octave Bioscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Progentec Diagnostics | 76% | |
| Amprion | 70% | |
| GLX Analytix | 70% |
Octave Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 4, 2025 | ||||
| Debt | Sep 4, 2025 | ||||
| Grant | Nov 15, 2023 | ||||
| Series B Extension | Jul 26, 2023 | ||||
| Series B | Dec 17, 2020 | ||||
Series A | Jul 12, 2018 |
Key People
Founding team and executive leadership
Octave Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| dRx Capital | Series B Extension |
| S32 | Series B Extension, Series C, Series A, Series B |
| Deerfield Management | Series B Extension, Series B |
| dRx Capital | Series B Extension |
| Blue Cross Blue Shield Association | Series B, Series A |
| Valhalla Foundation | Series C |
| Intermountain Ventures | Series B Extension, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 25, 2026
Monthly visitors grew 106% MoM, reaching 7.2K.
- Jan 8, 2026
Kirk Stockwood appointed as new Senior Vice President, Commercial.
Octave Bioscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Octave Bioscience's valuation, stock price, and market status.
Is Octave Bioscience a public or private company?
Octave Bioscience is a private company.
What is the current stock price of Octave Bioscience?
Octave Bioscience is a private company with no public stock price. No recent secondary market data is available.
How much is Octave Bioscience worth (valuation)?
Valuation information for Octave Bioscience is not publicly available.
Can I buy Octave Bioscience stock?
Octave Bioscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Octave Bioscience's last funding round?
Octave Bioscience's most recent funding round was Debt on September 4, 2025.
Who are the main investors in Octave Bioscience?
Key investors in Octave Bioscience include Blue Cross Blue Shield Association, Northpond Ventures, Blue Venture Fund.
Will Octave Bioscience IPO soon?
No public IPO plans have been announced for Octave Bioscience.
How can I track Octave Bioscience secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Octave Bioscience's secondary market activity and sign up for updates.